| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Itolizumab | T-1-hT; EQ-001; T-1-h; h-T1; Bmab-600 | Approved | Biocon Ltd, Center Of Molecular Immunology, Biotech Pharmaceuticals Co Ltd | Alzumab | India | Plaque psoriasis | Biocon Ltd | 2013-01-01 | Dermatomyositis; Graft vs Host Disease; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Respiratory Distress Syndrome, Adult; Psoriasis; Asthma; Plaque psoriasis | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



